title: Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
authors.affiliation: a Division of Hematology/Oncology , University of California , San Francisco , CA , USA.
authors.forename: Neel K
authors.initials: NK
authors.lastname: Gupta
authors.affiliation: a Division of Hematology/Oncology , University of California , San Francisco , CA , USA.|b Zuckerberg San Francisco General Hospital , San Francisco , CA , USA.
authors.forename: Chia-Ching
authors.initials: CC
authors.lastname: Wang
authors.affiliation: a Division of Hematology/Oncology , University of California , San Francisco , CA , USA.
authors.forename: Gabriel N
authors.initials: GN
authors.lastname: Mannis
authors.affiliation: c Department of Radiology , University of California , San Francisco , CA , USA.
authors.forename: John-Paul J
authors.initials: JJ
authors.lastname: Yu
authors.affiliation: a Division of Hematology/Oncology , University of California , San Francisco , CA , USA.|d Helen Diller Family Comprehensive Cancer Center , San Francisco , CA , USA.
authors.forename: James L
authors.initials: JL
authors.lastname: Rubenstein
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D024882:Drug Resistance, Viral; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide